Abstract Library

#4544 Spatial and temporal intratumour heterogeneity of pancreatic neuroendocrine tumours (PanNET)

Introduction: Data derived from the study of intertumour heterogeneity have led to propose that PanNET evolution may start either from beta cells with good prognosis, or from alpha cells with sequential alterations of MDA (MENIN-DAXX/ATRX) leading to more aggressive lesions.

Conference:

Presenting Author: Awan Z

Authors: Awan Z, Bourdeleau P, Epée J, Ps H, Tihy M,

Keywords: Pancreatic neuroendocrine tumour, Heterogeneity, Tumour microenvironment,

#4416 Medicine treatment of functional pancreatic neuroendocrine tumour with hypercalcaemia

Introduction: Functional pancreatic neuroendocrine tumours (F-PNETs) are capable of secreting parathyroid hormone-related protein (PTHrP), causing humoral hypercalcaemia of malignancy (HHM).

Conference:

Presenting Author: Yingmei T

Authors: Yanping Z, Jieting D, Yingmei T, Rongfang T, Yan W,

Keywords: functional pancreatic neuroendocrine tumour, parathyroid hormone related peptide, hypercalcaemia,

#3615 Clinicopathological features, treatment, and prognostic analysis of patients with gastrointestinal neuroendocrine neoplasms – A nation-wide clinical epidemiological study in China

Introduction: Nation-wide clinical epidemiological study on gastrointestinal neuroendocrine neoplasms (GI-NEN) in China is rare.

Conference:

Presenting Author: Yang H

Authors: Yang H, Xiao-Kun W, Su-Sheng S, Li-Ming J, Yihebali C,

Keywords: gastric neuroendocrine neoplasms, colorectal neuroendocrine neoplasms, Clinicopathological Features, Treatment,

#3117 Clinicopathological observation of gastric amphicrine carcinoma

Introduction: "Amphicrine carcinoma" refers to a mixed neoplasm composed of tumor cells with both exocrine and neuroendocrine differentiation. Up to now, the understanding of this kind of neoplasms is still limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Ma Y, Wang F, Song L, Zhao C,

Keywords: amphicrine carcinoma, neuroendocrine carcinoma, mixed neuroendocrine non-neuroendocrine neoplasm, stomach,

#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs

Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Budiawan H, Ali S, Hoersch D, Zachert C,

Keywords: Peptide Receptor Radionuclide Therapy (PRRT), thyroid cancer, survival, toxicity, response,